Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard) (“Formycon” or “the Company”) today provided an update on key developments across various biosimilar projects and invites ...

MiscellaneousFormycon AG informs about recent developments in various biosimilar projects and invites to conference call 17.02.2025 / 09:27 CET/CESTThe issuer is solely responsible for the content of ...

This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors, which have set new standards in cancer care in many different forms of the disease.

PLANEGG-MARTINSRIED I Germany I 17, 2025 I The Executive Board of Formycon AG (FSE: FYB, Prime Standard) (“Company”) has decided today to prematurely ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

Keytruda’s approval by the EMA comes on the back of the phase III KEYNOTE-054 trial, which showed that the drug reduced the risk of disease recurrence or death by 44% compared to placebo.

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

The cancer vaccine market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising number of cancer diagnoses, heightened awareness of cancer vaccines, ...

Enfortumab vedotin is marketed as Padcev (Astellas), and pembrolizumab is marketed as Keytruda (Merck). The combination, Powles said, “has doubled median progression-free survival and overall ...